These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2692018)

  • 21. The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer.
    Lee WA; Ennis RD; Longenecker JP; Bengtsson P
    Pharm Res; 1994 May; 11(5):747-50. PubMed ID: 8058647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of enhancers to increase nasal absorption using Ussing chamber technique.
    Hosoya K; Kubo H; Natsume H; Sugibayashi K; Morimoto Y
    Biol Pharm Bull; 1994 Feb; 17(2):316-22. PubMed ID: 7515747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of surfactants in the bioavailability of intranasal insulin.
    Sanchez A; Ygartua P; Fos D
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():120-4. PubMed ID: 1820865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of nasal absorption of insulin using chitosan nanoparticles.
    Fernández-Urrusuno R; Calvo P; Remuñán-López C; Vila-Jato JL; Alonso MJ
    Pharm Res; 1999 Oct; 16(10):1576-81. PubMed ID: 10554100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of multiple nasal administrations of bioadhesive powders on the insulin bioavailability.
    Callens C; Pringels E; Remon JP
    Int J Pharm; 2003 Jan; 250(2):415-22. PubMed ID: 12527167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutual inhibition of the insulin absorption-enhancing properties of dodecylmaltoside and dimethyl-beta-cyclodextrin following nasal administration.
    Ahsan F; Arnold JJ; Meezan E; Pillion DJ
    Pharm Res; 2001 May; 18(5):608-14. PubMed ID: 11465415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced intranasal insulin delivery by formulations and tumor protein-derived protein transduction domain as an absorption enhancer.
    Kim NA; Thapa R; Jeong SH; Bae HD; Maeng J; Lee K; Park K
    J Control Release; 2019 Jan; 294():226-236. PubMed ID: 30557648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human insulin plus sodium glycocholate in a nasal spray formulation: improved bioavailability and effectiveness in normal subjects.
    Pontiroli AE; Alberetto M; Pajetta E; Calderara A; Pozza G
    Diabete Metab; 1987; 13(4):441-3. PubMed ID: 3315765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation and characterization of insulin-loaded acrylic hydrogels containing absorption enhancers.
    Uchida T; Toida Y; Sakakibara S; Miyanaga Y; Tanaka H; Nishikata M; Tazuya K; Yasuda N; Matsuyama K
    Chem Pharm Bull (Tokyo); 2001 Oct; 49(10):1261-6. PubMed ID: 11605651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced ex vivo buccal transport of propranolol: evaluation of phospholipids as permeation enhancers.
    Lee J; Choi YW
    Arch Pharm Res; 2003 May; 26(5):421-5. PubMed ID: 12785740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study of nasal enzyme activity towards insulin. In vitro.
    Gizurarson S; Bechgaard E
    Chem Pharm Bull (Tokyo); 1991 Aug; 39(8):2155-7. PubMed ID: 1797441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nasal membrane and intracellular protein and enzyme release by bile salts and bile salt-fatty acid mixed micelles: correlation with facilitated drug transport.
    Shao Z; Mitra AK
    Pharm Res; 1992 Sep; 9(9):1184-9. PubMed ID: 1409402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic delivery of insulin via the nasal route using a new microemulsion system: In vitro and in vivo studies.
    Sintov AC; Levy HV; Botner S
    J Control Release; 2010 Dec; 148(2):168-76. PubMed ID: 20709120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal administration of human growth hormone (hGH) in combination with a membrane permeation enhancer in patients with GH deficiency: a pharmacokinetic study.
    Hedin L; Olsson B; Diczfalusy M; Flyg C; Petersson AS; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1993 Apr; 76(4):962-7. PubMed ID: 8473411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High absorbency and subchronic morphologic effects on the nasal epithelium of a nasal insulin powder dosage form with a soybean-derived sterylglucoside mixture in rabbits.
    Yamamoto T; Maitani Y; Ando T; Isowa K; Takayama K; Nagai T
    Biol Pharm Bull; 1998 Aug; 21(8):866-70. PubMed ID: 9743259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of polyamidoamine (PAMAM) dendrimers on the nasal absorption of poorly absorbable drugs in rats.
    Dong Z; Katsumi H; Sakane T; Yamamoto A
    Int J Pharm; 2010 Jun; 393(1-2):244-52. PubMed ID: 20417700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nasal absorption enhancement of 17 beta-estradiol by dimethyl-beta-cyclodextrin in rabbits and rats.
    Hermens WA; Deurloo MJ; Romeyn SG; Verhoef JC; Merkus FW
    Pharm Res; 1990 May; 7(5):500-3. PubMed ID: 2367318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promotion of nasal absorption of insulin by glycyrrhetinic acid derivatives. I.
    Mishima M; Okada S; Wakita Y; Nakano M
    J Pharmacobiodyn; 1989 Jan; 12(1):31-6. PubMed ID: 2656985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and evaluation of nasal formulations of ketorolac.
    Quadir M; Zia H; Needham TE
    Drug Deliv; 2000; 7(4):223-9. PubMed ID: 11195429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoglycaemic effect of a novel insulin buccal formulation on rabbits.
    Xu HB; Huang KX; Zhu YS; Gao QH; Wu QZ; Tian WQ; Sheng XQ; Chen ZX; Gao ZH
    Pharmacol Res; 2002 Nov; 46(5):459-67. PubMed ID: 12419651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.